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Effectiveness results
Peak expiratory flow (PEF) measurements increased by a mean difference of 9.1% (P=<0.001) in the FP group (little change in the control group). The median number of short-acting bronchodilator prescriptions was halved from 8 to 4 (P<=0.001) in the FP group. The proportion of FP patients prescribed 10 items or more fell by 19% (39). The median number of oral prednisolone prescriptions among FP patients fell from 1 to 0 (P=0.037), with zero courses increasing by 42% to 71%. Mean annualGP consultation figures fell by 50% to 2 (P=0.001) in the FP group, compared with the control group (remaining at 2 throughout). Mean asthma nurse attendance decreased over the period from 4 to 1 (P=0.006) in the FP group, in comparison with the control group where nurse attendance increased (mean difference 0.9, P=0.3). In the FP group the percentage of patients making five or more GP visits fell from 48% to 10% whilst the percentage of patients seeing the asthma nurse three or more times decreased from 72% to 34%.
Clinical conclusions
For asthmatics with persistent symptoms and frequent exacerbations, FP therapy can result in improved clinical outcomes.
Measure of benefits used in the economic analysis
The authors did not provide a summary measure of benefit. As such the benefits were assumed to be equivalent to the effectiveness results.
Direct costs
Direct costs included medication and management costs, based on practice and local authority estimates from 1994.
Currency

UK pounds Sterling (). No conversion was performed.
Sensitivity analysis
Not performed.
Estimated benefits used in the economic analysis
